Related Experiment Video
Updated: Jan 27, 2026

DNA Methylation: Bisulphite Modification and Analysis
Published on: October 21, 2011
Mutations in the DNA methylation pathway predict clinical efficacy to hypomethylating agents in myelodysplastic
Mengyi Du1, Fen Zhou2, Runming Jin2
1Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Purpose:
Myelodysplastic syndromes (MDS) are characterized by variable degrees of clinical outcomes. Until now, hypomethylating agents (HMAs) are the only drugs that have been approved by FDA in remedying this complicated prognosis disease, but without satisfactory outcome. So, biomarkers of better clinical outcome are of great significance. Many studies have already reported the potential prognostic value of DNA methylation pathway related gene (TET2/DNMT3 A/IDH) mutations in demethylation therapy patients, with controversial results. Therefore, a meta-analysis was performed to investigate their prognostic impact on HMAs treated MDS.
Methods:
Databases, including PubMed, Embase, web of science and the Cochrane Library, were searched for relevant studies published up to 29 May 2018. Overall response rate (ORR) and overall survival (OS) were selected as endpoints. We extracted odds ratio to evaluate the effect of mutations on ORR, and the corresponding hazard ratios and their 95% confidence intervals for OS.
Results:
A total of 13 cohort studies, covering 1398 patients with MDS treated by HMAs were included in the final meta-analysis. Our results indicated that DNMT3 A mutations had a favorable impact (P = 0.008) and TET2 mutations, which showed no significance (P = 0.06) in all included patients, could imply good efficacy in some subgroups on ORR. However, none advantages of mutations on ORR translated into a benefit in overall survival.
Conclusions:
This meta-analysis indicates one favorable factor, DNMT3 A mutations, on ORR in MDS patients with HMAs therapy. The identification of mutations in DNMT3 A can improve clinical efficacy and help make treatment decisions.
Related Concept Videos
Mutations
Mutations
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Viral Mutations
Mutation, Gene Flow, and Genetic Drift

